



PERFORMANCE UPDATE

1Q 2023

01

Company Overview



IDR 260,97 Billion

1Q 2023 Revenue (-3,08% yoy)



IDR 4,5 Billion

1Q 2023 Net Income for the Period (-19,6% yoy)

- Established in **1954** with more than **250 products** available in the market
- **Antimo** continues to be **the market leader** among competitors, dominating over **70% market share** in Antiemetic & Anti-Nausea treatment
- One of few Pharmaceutical Manufacturing Industries with **Certified Calibration Laboratory**

Shareholder Composition



Pareto Products

ANTIMO



- **Indications** : Nausea and vomiting during travelling by motor vehicles [car, bus], ships, and aircraft
- **Ingredients** : Dimenhydrinate tablet 50 mg
- **Packing** : 1 strip @ 10 tablets

BECEFORT



- **Indications** : Vitamin supplement of vitamin C, B, and Calcium deficiency i.e growth step, healing step, malnutrition, pregnancy and nursing women.
- **Ingredients** : Vit-B1, Vit-B2, Vit-B6, Vit-B12, Vit-C, Vit-E, Calcium
- **Packing** : 1 strip @ 4 caplets

TABLET TAMBAH DARAH



- **Indications** : For Iron Deficiency and to reduce megaloblastic anemia
- **Ingredients** : Ferrous Fumarate 180mg, Folic Acid 400mg
- **Packing** : 3 strips @ 10 tablets

PEHACAIN



- **Indications** : local anesthesia for dental procedures
- **Ingredients** : Lidocaine HCl 20mg, Epinephrine 0,0125mg
- **Packing** : 20 Ampoules @ 20ml

DEXTAMINE



- **Indications** : Corticosteroid Therapy and to relieve symptoms of allergies
- **Ingredients** : Dexamethasone 0,5mg, Dexchlorpheniramine maleate
- **Packing** : 30 blisters @ 10 caplets

PRO TB



- **Indications** : Treatment for TB Disease
- **Ingredients** : Rifampicin, Isoniazide, Pyrazinamide, Ethambutol
- **Packing** : 1 blister @ 28 film coated caplets

PANTOPRAZOLE



- **Indications** : Duodenal ulcer, gastric ulcer, reflux esophagitis
- **Ingredients** : Pantoprazole Sodium 124mg/Pantoprazole 40mg
- **Packing** : 1 vial @ 40mg

RANITIDINE



- **Indications**: Hypersecretory conditions
- **Ingredients** : Ranitidine 25 mg
- **Packing** : 25 Ampoules @ 2ml




02



Market Overview

Indonesia Economic Outlook

Indonesia's GDP for 2023

 4,5 – 5,0%

World Bank : 4,8%



OECD : 4,7%



IMF : 4,8%





ADB : 5,0%

Indonesia's economy is expected to grow by 4.8% in 2023 and 5.0% in 2024 as the commodity boom wanes and domestic demand normalizes.

(Asian Development Bank, 2023)

Indonesia Pharmaceutical Market Overview




The growth of the pharmaceutical market in Indonesia is predominantly driven by the ethical sector, which contributes 66% of the total market value of Rp 129.5 trillion.



03


Performance Highlight

Corporate Event Highlights



Winning multiple awards in various scopes of business categories, Phapros is always committed to providing the best for the community.

Financial Update




Despite having a small hiccup in Revenue & Net Income, Generic Drugs (OGB), one of the main contributors to PEHA overall sales, recorded an annual growth of 8.72 percent. On the other hand, an increase in the prescription drug segment (Ethical) achieved growth by 3.33 annually.



04

Business Strategy

Grand Strategy : 2023



BUMI UNTUK
INDONESIA

Phapros

THANK YOU
STAY HEALTHY

MANUFACTURING PLANT

PT PHAPROS TBK
Jl. Simongan No 131
Semarang 50148 INDONESIA
Phone : (62-24) 762 5484

HEAD OFFICE

PT PHAPROS TBK
Menara Rajawali Lantai 17
Jl. DR Ide Anak Agung Gde Agung
Mega Kuningan JAKARTA 12950 INDONESIA
Phone : +62 21 576 2709 | Fax : +62 21 576 3910



Phapros



phapros.id



PTPhapros



PT Phapros Tbk



www.phapros.co.id

AKHLAK

AMANAH

KOMPETEN

HARMONIS

LOYAL

ADAPTIF

KOLABORATIF